Backgrotmd: Dexmedetomldlne Is an a 2 agonlst wlth potential utUlty In clinical anesthesia for both its sedative and sympatholytlc properties.
Co11cl11sl o11s1
The lntrnmusculnr ndmlnlstratlon of dexmedetomldlne avoids the acute hemodynamlc changes seen with Intravenous administration, but results In similar hemody· namlc alter ations within ti h. (Key words: Hemodynamlcs. Pharmneoklnetlcs. SympathetJc nervous system, a 2 agonists: dexmedetomldlne.) THE a 2 -adrenergic agonists are a new class of potentially usefu l adjunctive anesthetic agents. Clonidine, the p rototypic a 2 -adrenergic agonist, is the most widely used drug of this c lass of compoun ds and decreases anesthetic and analgesic requirements In surgical pa· ticms.' Furthermore, clonidine administered b efore anesthetic induction may also minimize intraoperative h emodynamic fluctuations and is an effective anxio lytic agent. Because clonidine has a long duration o f action an d is a partial agon ist with only modest select ivity for the a 2 versus the a, adrenoceptor , a second generation of a 2 agonists is now being developed in an attempt to overcome the p erceived shortc omings of clonidine in anesthetic settings. Dcxmedetomidine (1,620: 1 [a 2 : a 1 ]) is more selective at the a 2 adrenoceptor t han is clonidine (220:1) and is a full agonist.
2
To administer dexmedetomidine accurately, it is n cccs:sary to characterize the p harmacokinctic pcofilc u si ng r elevan t doses via the in tended routes of administration, and to correlate side effects, such as hemod ynam ic alterations , w ith the plasma con centrations of medication. Using a crossover study design , with dexmedetomidine administered intravenously and intramuscularly, we characterized d exmedetomldine p harmacokinetics and h emodynamic a lterat ions in ten healthy adult volunteers.
Materials and Methods

Su bjects
After approval by t he Stan ford University Investigational Review Board, ten healthy male v olunteers were recruited for this study. The average age of the subjects was 35.5 yr (range 29-44 yr) and the average weight Downloaded From: bttp:/lanestbesiology.pubs.asabq.org/pdfaccess.asbx?ul'l=/data/Joumals/J ASA/931315/ on 08/09/2016 was 79 kg (range 60-98 kg). Male subjects between the ages of 18-50 yr, with weight less than 100 kg and ASA physical status 1-2, were eligible for study.
The volunteers were fasted from midnight before the study and were asked to abstain from any caffeine or alcohol consumption for the preceding 24 h. On arrival at the study site, an l S·G intravenous cannula was in· serted, and 500 ml normal saline was rapidly infused, followed by an infusion at 125 ml/h. A 20-G catheter was ·inserted into the radial artery and used both to measure arterial blood pressure and to sample blood for analysis of plasma dexmedetomidine concentra· tions. After fluid loading, 2 µg/kg dexmedecomidine hydrochloride was administered intravenously with an infusion pump at a constant rate over 5 min. Subjects were kept in the supine position in a quiet room and disturbances were minimized until the initial 4 h of recording was completed. A minimum of 2 weeks after the intravenous study, the volunteer was given the same dose of dexmedetomidine as a single intramuscular injection into the deltoid muscle over 30 s during an otherwise similar study procedure.
Blood Sampling
Arterial blood was sampled at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5, 6, 8, 10, 12, 15, 20, 30, 45, 60, 90, 120, 180 , and 240 min after the start of the intra· venous infusion. The blood pressure transducer was exposed to valid arterial pressure waveform for at least 15 s between each of the blood samples obtained dur· ing the first 5 min of the intravenous infusion. During the intramuscular phase of the study, blood was sampled at 2 , 5, 10, 15, 20, 30, 45, 60, 90, 120, 180 , and 240 min after injection. Venous blood during both phases was sampled at 180, 240, 300, 450, 600, 900, 1,200, and 1,440 min. The 5-ml K 2 EDTA anticoagu· lated samples were centrifuged and the plasma frozen at -40° C until the dexmedctomidine concentration was assayed. Blood sampling changed from arterial to venous at 4 h to minimize the length of time the vol· umcers were subjected to the presence of an arterial line.
Dexmetletomidine Assay
The plasma was assayed for dexmedetomidine concentration using a gas chromatograph (GC) with mass spectroscopy (MS) detection. 3 The pentatluorobenzoyl derivatives of dexmedetomidlne and the internal stan· dard detomidine were produced during extraction of the plasma into n-hexane in the presence of Na 2 C0 3 Ancsthcslolob'Y· V 78, No 5, May 1993 and pentafluorobenzoyl chloride. The organic phase was evaporated and the residue reconstituted in tolu· enc. A l·ul aliquot was injected onto a Hewlett-Packard fused silica capillary column cross linked with 5% phenyl methyl silicone (Part number 19091)-102, Hewlett-Packard Company, Little Falls, DE) of a Hewlett-Packard gas chromatograph (Model 5890A, Hew· lctt·Packard Company, USA) using helium as the carrier gas. The GC oven was programmed for 1 min at 90° C and 30° C/min up to 275° C with a 5.8-min hold at 275° C. The MS (Finnigan MATTSQ 70, Finnigan MAT) using methane as the carrier gas was operated in negative ion chemical ionization and selected ion moni· toring mode with 70 eV ionization energy at 200° C. The pentafluorobenzoyl derivatives of detomidine were detected at 380.1 (mass/charge ratio) and dexmede· tomidine at 394. I. The lower limit of quantltation for this GC/MS technique was 50 pg/ml, recovery of tri· tiated dexmedetomidine was 81 %, and the coefficient of variation for within-day assays at 7 5 pg/ml was 12%, at 350 pg/ml was 9%, and at 600 pg/ml was 17.1%. The coefficient of variation for between-day assays at 212 pg/ml was 12.8%, and at 537 pg/ml was 11.3%. When three extractions were injected into the GC/MS system ten times each, at 75, 350, and 600 pg/ml, respectively, the coefficient of variation was 9.7%, 7 .5%, and 11.3%, respectively.
Pbarmacoktnetic Analysts
Moment Analysis. Moment analyses were performed on both the intravenous and intramuscular data to calculate the model independent parameters: area under the concentration versus time curve (AUC), :1rea under the first moment of the concentration versus time curve (AUMC), clearance (Cl), volume of distribution (Vd.,), and mean residence time (MRT). Values for AUC and AUMC are intermediate steps in the calculations and arc presented for the sake of continu ity. The AUC was calculated using the trapezoidal method with linear interpolation when concentrations were increasing and log-linear interpolation when concentrations were de· creasing. 4 At time points where both arterial and venous concentrations were obtained, the venous values were used in the trapezoidal integration. Extrapolation from the terminal data point to infinity was accomplished using log-linear regression of the terminal elimination phase and is presented as the terminal elimination half· life or In (2) divided by the slope of the terminal phase. In similar fashion, the AUMC was calculated as the trapezoidal integration of the cu rve generated by mul· tiplying each p lasma concentration by its time. The volume of distribution at steady state was calculated as follows: 5
where T was the duration of the infusion. Clearance was calculated as the ratio of dose to AUC: 5 
CL= Dose AUC'
and MRT as the ratio of Vd .. , to clearance:
The bloavallabillty of Intramuscular dexmede1om!dlne was calculated as the ratio of the AUC after intramuscular versus intravenous administration of the same dose:
toavat a 1 tty = ---X 1 .
AUC1i11
Deconvolution Analysis. Based on the assumption that the pharmacokinetics of dexmedetomidine are linear and stationary, but making no assumptions about model structure, the absorption characteristics of intramuscular dexmedetomidine were determined through least-squares deconvolution of the intramuscular concentration versus time function w ith the intravenous unit disposition function (UDF) 6 • 7 for each individual patient. Knowing that;
where Cp is the concentration in the plasma, I is the input function, and D is the unit disposition function, the known zero order intravenous infusion of dexmedetomidine can be deconvolved against the plasma versus time concentration profile to produce the in· travenous-UDF. The deconvolution was constrained to be positive and unimodal.
Arterial Wave Form Recording and Analysis
The radial artery cannula was connected to a Deltran II transducer (Model 901-007, Utah Medical Products Inc., Midvale, Utah) on a Hewlett-Packard 78353A monitor. Analog output from the HP monitor was recorded by a TEAC R-71 recorder and simultaneously digitized on a DT280 I Data Translation A/D board at 128 Hz with 12-bit resolution to the hard disk o f an Anesthesiology, V 78, No 5, May 1993 80386-based computer. Calibration signals were recorded from a Delta-Cal Transducer Simulator (Model 650-905, Midvale, Utah) at 0, 50, 100, 150, and 200 mmHg. The digitized binary file was read and analyzed with software that located the peak and trough of each wave, and calculated the MAP by integrating the area beneath the wave. The algorithm has specific criteria that define a wave, and rejected signals caused by opening the stopcock to draw a blood sample or flush· ing the arterial catheter. The heart rate was calculated as the reciprocal of the time interval between-. wave peaks. The systolic and diastolic blood pressure, MAP, and heart rate were recorded for each wave on the arterial pressure trace during the study. The · hemodynamic data reported represents the median MAP and heart rate values for each 60-s period.
Results Figure 1 shows the de:xmcdetomidine plasma concentration versus time profiles for all ten volunteers during the 5-min intravenous infusion and for the following 24 h. At 3 and 4 h after the infusion, simultaneous arterial and venous blood samples were drawn. This allowed us to remove the arterial catheter from the subject while still sampling pharmacokinetic data. The venous concentrations were consistently higher than the arterial concentrations, as would be expected during the elimination phase of the pharmacokinetic profile. 8 The rise in plasma concentration was probably not elution from storage sites in skeletal muscle, because the subjects remained supine from the start of No.
(ng ·min· ml"') (min) • Subject 1 excluded from summaiy statistics.
the study until the 240-min sample, and were only starting to ambulate by 300 min. The plasma dexme· detomldine concentrations after intravenous adminis· Cration decreased to less than the limit of quantltation in six patients by 20 h after administration. Moment analysis of the intravenous data for the ten subjects is presented in table 1. The MRT of subject 1 was so long that 24-h sampling did not adequately characterized the AUC. The AUC data for this subject encompassed only 62% of the total area and the AUMC 19%. The means of the moment analysis, therefore, do not include this subject. The mean clearance was 0. 511 ± 0.125 L/min, Vd .. was 194 ± 28.7 L, andMRTwas 401±112min. figure 2 shows the plasma concentration versus time profile after intramuscular administration of 2 ,ug/kg dexmedetomidine. The time to peak plasma concentration was 13 ± 18 min and the mean peak concentration was 0.81 ± 0 .27 ng/ ml (table 2). The variability in peak and time to peak concentrations was high. This was due, in large part, to the first two subjects who showed slower absorption with longer time to peak concentrations and lower peak concentrations. If the mean values are recalculated to include only subjects 3-10, the time to maximum concentration was 6.1 ± 4.4 min and the maximum concentration was 0.91 ± 0.22 ng/ml. The average area under the concentration vetsus time curve for all subjects was 243 ± 78 ng · min-1 • m1-1 and the average bioavailability was 73 ± 11% (table 2) .
The concentration versus time profile for the intra- known zero order input function to arrive at the calculated unit disposition function (UDF) for each subject. Deconvolution was constrained to be positive and unimodal to restrict the output to physiologically meaningful results. Figure 3 shows average intravenous-UDF (±SD) of the ten subjects calculated through the deconvolution technique. The resulting UDP for dexmedetomidine after intravenous administration was deconvolved against the concentration versus time profile after intramuscular administration on a patientby-patient basis to produce the rate of intramuscular absorption shown in figure 4 . Integration of the absorption rate over time after intramuscu lar injection (figure 4) yields a total systemic dose of 13 3 µg and a bioavailability of 84% (133 µg systemically absorbed/ 158 µg average intramuscular dose). Figure 5 shows the cumulative absorption over time, as a percent of total absorption. The mean intramuscular dose was 158 µg resulting in a bioavailability of intramusclllar-to-intravenous dosing of 84% using deconvolution analysis. venous dcxmcdctomidine occurred at S min and was 22% above baseline values. A much smaller increase in MAP occurred after intramuscular injection, but was even earlier in onset and was probably caused by the anxiety induced by the intramuscular injection. By 4 h, both intravenous and intramuscular dexmedetomidine resulted in a 20% decline in MAP from baseline. The blood pressure disturbance at 140-150 min was caused by subjects waking up abruptly, rather than by ambulation of the subjects. Figures 8 and 9 show the mean heart rate (±SD) for the ten volunteers after intravenous and intramuscular dexmedetomidinc, re· spectively. The decline in HR after intravenous dexmedetomidine was 27% below baseline 4-5 min after starting the infusion. Again, this was not seen after In· tramuscular injection. Dexmedetomidine given by intramuscular and intravenous routes caused a 5% and 10% decline in HR, respectively, by the end of the 4-h recording period.
Discussion
Hemodynamic alterations after intravenous administration preclude the use of dexmedetomidinc as a rapid intravenous infusion or bolus. Compartmental pharmacokinetic analysis would be required to administer dexmedecomlcline via a computer-comrolled infusion pump, but dexmcdctomid inc would be more tensive tissue distribution (fentanyl Vd., approximately 300 L) and a moderately large hepatic clearance (i.e., large CL). The MRT is a term unfamiliar to many anes· thesiologists, but one that might serve a useful purpose for comparison of medications given the misleading characteristics of the compartmental elimination half. life. 10 The MRT ls the moment analysis equivalent of the half-life in compartmental analysis and represents the time required to eliminate 63.2% of an intravenous bolus dose. The effective half-life of a medication is 0.693 times the MRT.
The bioavailability of intramuscular dexmedetomidine was between 70% and 80%. On average, peak plasma concentrations of dexmedetomidine were ob· tained within l 5 min after intramuscular injection, although the time to peak concentration after intramuscular injection varied widely. The intramuscular absorption prolile was b iphasic with early rapid absorption.
Intravenous dexmedecomldine as a rapid infusion caused bi phasic changes in HR and MAP similar to those seen after administration of clonidine. 11 • 12 The clinical utility of intravenous dexmedetomidine will be limited by these hemodynamic alterations. Bolus intravenous administration of dexmedetomidine would be unwise in most circumstances. It is possible that dexmedetomid in e pharmacokinetics are not linear secondary to the concentration·dependent hemodynamic alterations. Many of the drugs used in anesthesia practice (i.e., propofol and thiopental) affect hemodynamics and probably have nonlinear pharmacokinetics. Thus, the as- sumption of linearity is violated frequently in both compartmental pharmacokinetic analysis and moment analysis. As violation of linearity is part of model misspecification, the magnitude of such a violation can be roughly estimated from the size of the residual error when compartmental models are fit to the data. In practice, most pharmacokinetic studies simply ignore the issue of nonlinear pharmacokinetics because the extent of the violation is fairly small, and pharmacokinetics based on the assumption of linearity provide a succinct, easily estimated, and clinically useful description of pharmacokinetic behavior. The hypertension and bradycardia seen after intravenous dexmedetomidine were not seen after intramuscular administration.
The peak plasma concentrations were an order of magnitude lower after intramuscular administration. On the assumption that the differences in hemodynamic profiles may have been a result of concentration-dependent peripheral vasoconstriction, one might strive to maintain a plasma dexmedetomidine concentration of less than 1.0 ng/ml. From the presented moment analysis data, and knowing that clearance times targeted concentration will yield a corresponding infusion rate, the steady-state concentration of 1.0 ng/ml cou ld be achieved through an infusion of dexmedetomidine at 0. 511 µg/min. The plasma concentration will asymptotically approach the targeted steady-state concentration of 1.0 ng/ml and would be very close to the steadystate concentration after three elimination hall-lives or 1, 1 5 5 min. If it is desirable to attain the target concentration b efore 19.25 h, a loading dose, calculated as targeted steady-state concentration times Yd« or 194 µg, may be administered and followed by the maintenance infusion. The loading dose should not be administered as a bolus, but can be given as an infusion over 30-45 min with minimal increased risk of adverse hemodynamic alterations.
Two subjects lost consciousness when they assumed the upright posture, approximately 5 h after the intra· venous infusion of dexmedetomidine. During these events, both subjects had bradycardia. The likely etiology for this loss of consciousness is the sympatholytic effect of the dexmedetomidine leaving unopposed vagal tone. Both subjects recovered from their vasovagal events spontaneously and uneventfully. No analogous events occurred after intramuscular administration, but increased caution on the part of both the investigators and the subjects during the second phase of the study may have prevented slmllar episodes. We conclude that, although intramuscular absorption of dexmedetomidine is rapid, the peak plasma concentrations that result arc less than those after a 5-min intravenous infusion with the same dose, and hemodynamic alterations are less severe.
